CD274 and neoplasm: Studies after studies proved the higher incidence and severity of irAE with CTLA4 inhibitors when used alone or combined with PD-1 or PD-L1 agents such as ipilimumab and nivolumab irrespective of the primary tumor treated (22, 65–67).